Pulling a page from ancient Rome’s military handbook, investigators in the DF/HCC Breast Cancer Program are deploying a divide-and-conquer strategy in the battle against... | [more]
Announcements
- Julio Frenk named next dean of Harvard School of Public Health Posted: 08-06-08
- Cancer Research Collaboration Committee Looking for New Members Posted: 06-16-08
- Advance Notice: Breast SPORE Competitive Renewal Posted: 06-09-08
- DF/HCC Member Survey Raffle Winners Posted: 06-05-08
- Harvard receives transforming NIH award Posted: 06-02-08
- Core facilities at DF/HCC Posted: 05-27-08
News
Divide-and-conquer strategy drives breast cancer breakthroughs
siRNA knockdowns turn up intriguing HER2 targets
At best, only 20 to 30 percent of women with HER2-positive breast cancer respond to trastuzumab. That grim reality has prompted the Breast Cancer Program to search for new... | [more]
Fusion vaccine plus surgery may prove potent combination in renal cell cancer
Renal cell cancer (RCC) is a life-threatening malignancy considered incurable in the metastatic setting. While standard chemotherapy has proved largely ineffective,... | [more]
Specialized Histopathology Services Core
The Specialized Histopathology Services (SHS) Core provides technical and professional pathology services in a variety of experimental organisms and human tissues. Specific... | [more]
